Clinical efficacy of Calcium sodium edetate and Low-Dose sodium dimercaptopropanesulfonate in neurological Wilson disease
- VernacularTitle:依地酸钙钠与小剂量二巯丙磺酸钠在脑型Wilson病中的驱铜疗效对比研究
- Author:
Jun LI
1
;
Huaizhen CHEN
1
;
Yafei HU
1
Author Information
- Publication Type:Journal Article
- Keywords: Wilson’s disease; Sodium 2; 3-dimercapto-1-propane sulfonate; Calcium sodium edetate; Neurological Deterioration; Adverse reactions
- From: Journal of Apoplexy and Nervous Diseases 2022;39(3):245-246
- CountryChina
- Language:Chinese
- Abstract: To compare the clinical efficacy of calcium sodium edetate （EDTA） and the low-dose sodium dimercaptopropanesulfonate（DMPS） in treating cerebral Wilson’s disease. Methods Eighty patients with neurological Wilson’s disease in the neurology department of the first affiliated hospital of Anhui traditional Chinese medicine from February 2019 to September 2021 were collected and divided into the EDTA treatment group（n=39） and the low-dose DMPS control group（n=41）based on treatments. Propensity score matching （PSM） was performed on the two groups of patients and the results were compared after matching. The copper displacement effects of the two groups were compared，and the deterioration of copper displacement and adverse reactions were observed. Results After PSM，35 patients in EDTA group and 35 patients in the low-dose DMPS group were included. UWDRS Ⅰ in EDTA group showed significant statistical difference after treatment［（57.03±21.06） versus （54.40±20.02），t=7.256，P<0.001］，while UWDRS Ⅰ in the low-dose DMPS group showed no significant statistical difference［（53.49±26.82） versus （52.37±27.17），t=1.544，P=0.129］. Compared with the low-dose DMPS group，there was no significant difference in 24-hour urinary copper detection in the EDTA group［551.18 （417.77，843.47） versus 489.20 （389.64，839.47），Z=0.029，P>0.05］. The neurological deterioration （P=0.025） and adverse reactions were significantly reduced. Conclusion EDTA and low-dose DMPS have the same effect in expelling copper in patients with neurological WD，with better improvement，less neurological deterioration probability，and fewer adverse reactions. EDTA can be used as a copper removing treatment for patients with neurological WD.
- Full text:2024072610123931338Clinical efficacy of Calcium sodium edetate and LowDose sodium dimercaptopropanesulfonate in neurological Wilson disease.pdf
